Abstract
Human ADA2 deficiency (DADA2) is an inborn error of immunity with a broad clinical phenotype which encompasses vasculopathy including livedo racemosa and lacunar strokes, as well as hemato-immunological features. Diagnosis is based on the combination of decreased serum ADA2 activity and the identification of biallelic deleterious alleles in the ADA2 gene. DADA2 carriers harbor a single pathogenic variant in ADA2 and are mostly considered healthy and asymptomatic. However, some DADA2 carriers present a phenotype compatible with DADA2. Here, we report ten patients from seven kindreds presenting with a phenotype indicative of DADA2, in whom only a single pathogenic variant (p.G47R, p.G47V, p.R169Q, p.H424N) was identified. To test whether being heterozygote for specific variants could explain the patients’ phenotype, we investigated the effect of the ADA2 missense variants p.G47A, p.G47R, p.G47V, p.G47W, p.R169Q, p.E328K, p.T360A, p.N370K, p.H424N and p.Y453C on ADA2 protein expression, secretion and enzymatic activity. Functional studies indicate that they exert a dominant negative effect on ADA2 enzymatic activity, dimerization and/or secretion. At the molecular level, heterozygosity for these variants mimics what is observed in DADA2. We conclude that humans with heterozygous dominant negative missense variants in ADA2 are at risk of DADA2.
Competing Interest Statement
LRD KU Leuven receives advisory board honorary from Boehringer-Ingelheim and Takeda for IM. IM is the chair of the CSL Behring Chair in Primary Immunodeficiencies, paid to KU Leuven.
Funding Statement
IM is a Senior Clinical Investigator at the Research Foundation FWO Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies through KU Leuven, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received funding from the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation programme (grant agreement No. 948959). This work is supported by ERN RITA. LE was supported by a PhD Fellowship from the Research Foundation FWO Flanders (grant 11E0123N). LE is a fellow of the BIH Charite Junior Clinician Scientist Program funded by the Charite Universitatsmedizin Berlin, and the Berlin Institute of Health at Charite (BIH). MEK and YI were funded by the Charles Bronfman Institute for Personalized Medicine at Icahn School of Medicine, Mount Sinai. This work was supported in part through the computational and data resources and staff expertise provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the National Center for Advancing Translational Sciences. This research was conducted using the UK Biobank resource under application number 53074. WVE acknowledges funding of FWO Grant G095522N was used for this research. RS is supported by an FWO senior clinical investigator fellowship (1805523N).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee for Research of Leuven University Hospitals (project numbers: S51577, S63077).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict-of-interest statement:
LRD KU Leuven receives advisory board honorary from Boehringer-Ingelheim and Takeda for IM. IM is the chair of the CSL Behring Chair in Primary Immunodeficiencies, paid to KU Leuven.
